Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Ziopharm Oncology (ZIOP), Fate Therapeutics (FATE) and Kura Oncology (KURA).
Ziopharm Oncology (ZIOP)
H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on Ziopharm Oncology today and set a price target of $5.50. The company’s shares closed yesterday at $2.95.
Ramakanth observed:
“We are maintaining our Buy rating of ZIOP and our 12- month price target of $5.50 per diluted share. We derive our price target based on a risk-adjusted net present value analysis of projected product revenues until 2027 assuming a 12% discount rate and a 4% terminal growth rate.”
According to TipRanks.com, Ramakanth has 0 stars on 0-5 star ranking scale with an average return of -3.1% and a 35.1% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Collplant Holdings Ltd, Leap Therapeutics Inc, and Tyme Technologies Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Ziopharm Oncology with a $5.50 average price target.
See today’s analyst top recommended stocks >>
Fate Therapeutics (FATE)
In a report released today, Edward White from H.C. Wainwright maintained a Hold rating on Fate Therapeutics, with a price target of $12. The company’s shares closed yesterday at $16.03.
White commented:
“Our $12 price target is based on a sum-of-the-parts analysis based on probability-adjusted revenue forecasts for ProTmune and FATE-NK100. We use the net present value of our revenue forecast through 2027, apply a 40% probability of success for and year-end 2019 diluted net cash estimate of $1.44/share to arrive at our $12 price target. We value the early stage pipeline which includes the Juno collaboration, at $2.50/share. We assume a 25% discount rate for the NPV of the pipeline and a P/S multiple of 4x.”
According to TipRanks.com, White is a 5-star analyst with an average return of 13.6% and a 47.5% success rate. White covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Spectrum Pharmaceuticals, and Synthetic Biologics Inc.
Currently, the analyst consensus on Fate Therapeutics is a Moderate Buy with an average price target of $23.
Kura Oncology (KURA)
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Kura Oncology today and set a price target of $31. The company’s shares closed yesterday at $14.81.
Pantginis said:
“Valuation and impediments to achieving price target. We reiterate our Buy rating and $31 price target. The primary contributor to our valuation is tipifarninb (93.9%). Of tipifarnib’s contribution, 46.7% comes from the lead opportunity in HNSCC, with the remainder coming from the other indications currently being pursued (i.e., and CMML. The remainder, or 6.1% of our valuation comes from KO-947, reflective of its early stage Phase 1 status.”
According to TipRanks.com, Pantginis is ranked 0 out of 5 stars with an average return of -16.3% and a 27.6% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Iovance Biotherapeutics Inc, and Checkpoint Therapeutics Inc.
Currently, the analyst consensus on Kura Oncology is a Moderate Buy with an average price target of $29.50, implying a 99.2% upside from current levels. In a report released yesterday, Oppenheimer also assigned a Buy rating to the stock with a $28 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
